Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072700 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL9356684 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL3421963 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL5495466 | 0.78 | CYP3A4 (0.49) | METAP2METAP1GAANPC1ENPP1 | |
| SCHEMBL4517474 | 0.78 | METAP2 (0.39) | METAP2METAP1NPY5RENPP1ALDH1A1 | |
| SCHEMBL28139921 | 0.77 | METAP2 (0.41) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL3426596 | 0.77 | METAP2 (0.41) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL5436671 | 0.77 | METAP2 (0.41) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL2789821 | 0.76 | METAP2 (0.40) | METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL6675320 | 0.75 | METAP2 (0.39) | METAP2METAP1NPY5RENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112912378-B | Hydrazinopurine compounds and triazolopurine compounds for inhibiting xanthine oxidase | 泰拉强石株式会社 | 2023-09-12 | — | — | CN | claimed |
| US-20210347778-A1 | HYDRAZINOPURINE COMPOUND AND TRIAZOLOPURINE COMPOUND FOR INHIBITING XANTHINE OXIDASE | TERA STONE CO., LTD (JP) | 2021-11-11 | — | — | US | claimed |
| EP-3845535-A1 | HYDRAZINOPURINE COMPOUND AND TRIAZOLOPURINE COMPOUND FOR INHIBITING XANTHINE OXIDASE | Tera Stone Co., Ltd (JP) | 2021-07-07 | — | — | EP | claimed |
| CN-112912378-A | Hydrazinopurine compounds and triazolopurine compounds for inhibiting xanthine oxidase | 泰拉强石株式会社 | 2021-06-04 | — | — | CN | claimed |
| WO-2020045558-A1 | HYDRAZINOPURINE COMPOUND AND TRIAZOLOPURINE COMPOUND FOR INHIBITING XANTHINE OXIDASE | テラ・ストーン株式会社 | 2020-03-05 | — | — | WO | claimed |
| US-7034016-B2 | 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-04-25 | — | — | US | claimed |
| EP-1198464-B1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2003-10-08 | — | — | EP | claimed |
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2003-03-27 | — | — | US | claimed |
| EP-1198464-A1 | 8-PHENYL-6,9-DIHYDRO- 1,2,4]TRIAZOLO 3,4- i i /i ]PURIN-5-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2002-04-24 | — | — | EP | claimed |
| WO-2001007441-A1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2001-02-01 | — | — | WO | claimed |
| EP-3845535-B1 | HYDRAZINOPURINE COMPOUND AND TRIAZOLOPURINE COMPOUND FOR INHIBITING XANTHINE OXIDASE | TERA STONE CO LTD (JP) | 2024-06-26 | — | — | EP | disclosed |
| CN-112912378-B | Hydrazinopurine compounds and triazolopurine compounds for inhibiting xanthine oxidase | 泰拉强石株式会社 | 2023-09-12 | — | — | CN | disclosed |
| CN-112912378-B | Hydrazinopurine compounds and triazolopurine compounds for inhibiting xanthine oxidase | 泰拉强石株式会社 | 2023-09-12 | — | — | CN | disclosed |
| CN-116693394-A | Dehydrazine method and application | 大连理工大学 | 2023-09-05 | — | — | CN | disclosed |
| JP-2023071839-A | HYDRAZINOPURINE COMPOUND AND TRIAZOLOPURINE COMPOUND FOR INHIBITING XANTHINE OXIDASE | テラ・ストーン株式会社 | 2023-05-23 | — | — | JP | disclosed |
| US-7034016-B2 | 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-04-25 | — | — | US | disclosed |
| EP-1198464-B1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2003-10-08 | — | — | EP | disclosed |
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2003-03-27 | — | — | US | disclosed |
| EP-1198464-A1 | 8-PHENYL-6,9-DIHYDRO- 1,2,4]TRIAZOLO 3,4- i i /i ]PURIN-5-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001007441-A1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | HYOU1, CHN2, PURB | METAP2 1777/4885METAP1 1107/4885GAA 4843/4885 |
| US-20210347778-A1 | HYDRAZINOPURINE COMPOUND AND TRIAZOLOPURINE COMPOUND FOR INHIBITING XANTHINE OXIDASE | XDH, HPRT1, TPMT | METAP2 255/4885METAP1 111/4885GAA 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.